See more : Arcadyan Technology Corporation (3596.TW) Income Statement Analysis – Financial Results
Complete financial analysis of Vertex, Inc. (VERX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Vertex, Inc., a leading company in the Software – Application industry within the Technology sector.
You may be interested
- Touchwood Entertainment Limited (TOUCHWOOD.NS) Income Statement Analysis – Financial Results
- Nilar International AB (NILRF) Income Statement Analysis – Financial Results
- Intesa Sanpaolo S.p.A. (ISNPY) Income Statement Analysis – Financial Results
- TBK Co., Ltd. (7277.T) Income Statement Analysis – Financial Results
- 24SevenOffice Group AB (publ) (TFSVF) Income Statement Analysis – Financial Results
Vertex, Inc. (VERX)
About Vertex, Inc.
Vertex, Inc. provides tax technology solutions for corporations in retail, communication, leasing, and manufacturing industries in the United States and internationally. It offers tax determination, compliance and reporting, tax data management, document management, pre-built integration, and industry-specific solutions. The company sells its software products through software license and software as a service subscriptions. It also provides implementation and training services in connection with its software license and cloud subscriptions, transaction tax returns outsourcing, and other tax-related services. Vertex, Inc. was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 572.39M | 491.62M | 425.55M | 374.67M | 321.50M | 272.40M |
| Cost of Revenue | 223.81M | 193.13M | 161.89M | 165.39M | 110.38M | 95.70M |
| Gross Profit | 348.58M | 298.49M | 263.66M | 209.28M | 211.12M | 176.71M |
| Gross Profit Ratio | 60.90% | 60.72% | 61.96% | 55.86% | 65.67% | 64.87% |
| Research & Development | 58.21M | 41.88M | 44.02M | 54.34M | 30.56M | 23.76M |
| General & Administrative | 145.94M | 121.65M | 107.01M | 149.06M | 71.01M | 58.95M |
| Selling & Marketing | 140.24M | 125.34M | 99.01M | 99.42M | 68.13M | 56.90M |
| SG&A | 286.17M | 246.99M | 206.01M | 248.48M | 139.14M | 115.85M |
| Other Expenses | 21.70M | 17.71M | 16.57M | 11.22M | 9.57M | 7.25M |
| Operating Expenses | 366.09M | 306.57M | 266.60M | 314.04M | 179.27M | 146.85M |
| Cost & Expenses | 579.81M | 499.71M | 428.49M | 479.42M | 289.65M | 242.54M |
| Interest Income | 0.00 | 1.68M | 984.00K | 1.72M | 1.08M | 526.00K |
| Interest Expense | 4.16M | 2.05M | 984.00K | 3.11M | 2.04M | 1.59M |
| Depreciation & Amortization | 74.46M | 76.28M | 56.73M | 32.22M | 25.19M | 24.90M |
| EBITDA | 56.95M | 53.07M | 41.84M | -72.54M | 58.13M | 22.07M |
| EBITDA Ratio | 9.95% | 10.80% | 9.83% | -19.36% | 18.08% | 20.10% |
| Operating Income | -7.42M | -8.08M | -2.94M | -104.76M | 31.86M | -2.83M |
| Operating Income Ratio | -1.30% | -1.64% | -0.69% | -27.96% | 9.91% | -1.04% |
| Total Other Income/Expenses | -14.25M | -2.05M | -984.00K | -3.11M | -953.00K | -34.41M |
| Income Before Tax | -21.67M | -10.13M | -3.93M | -107.87M | 30.90M | -4.43M |
| Income Before Tax Ratio | -3.79% | -2.06% | -0.92% | -28.79% | 9.61% | -1.63% |
| Income Tax Expense | -8.58M | 2.17M | -2.45M | -28.93M | 7.83M | 1.68M |
| Net Income | -13.09M | -12.30M | -1.48M | -78.94M | 23.08M | -6.11M |
| Net Income Ratio | -2.29% | -2.50% | -0.35% | -21.07% | 7.18% | -2.24% |
| EPS | -0.09 | -0.08 | -0.01 | -0.54 | 0.21 | -29.08 |
| EPS Diluted | -0.09 | -0.08 | -0.01 | -0.54 | 0.21 | -29.08 |
| Weighted Avg Shares Out | 151.86M | 149.65M | 147.78M | 146.44M | 146.17M | 210.00K |
| Weighted Avg Shares Out (Dil) | 151.86M | 149.65M | 147.78M | 146.44M | 146.17M | 210.00K |
The Zacks Analyst Blog Vertex Pharmaceuticals CRISPR and Moderna
Vertex Pharmaceuticals CRISPR and Moderna are included in this Analyst Blog.
Vertex Announces CASGEVY™ Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia in England
LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible transfusion-dependent beta thalassemia (TDT) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY™ (exagamglogene autotemcel), from today. The reimbursement agreement comes as the National Institute for...
Vertex, Inc. (VERX) Q2 2024 Earnings Call Transcript
Vertex, Inc. (NASDAQ:VERX ) Q2 2024 Results Conference Call August 7, 2024 8:30 AM ET Company Participants Joe Crivelli - VP, IR David DeStefano - President and CEO John Schwab - CFO Conference Call Participants Brad Reback - Stifel Joshua...
Vertex (VERX) Tops Q2 Earnings and Revenue Estimates
Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.08 per share a year ago.
Vertex Acquires ecosio To Accelerate Global E-Invoicing Compliance
Delivering a Seamlessly Connected Global Platform to Manage Continuous Compliance Delivering a Seamlessly Connected Global Platform to Manage Continuous Compliance
Vertex Announces Second Quarter 2024 Financial Results
KING OF PRUSSIA, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its second quarter ended June 30, 2024.
Is It Too Late to Buy Vertex Pharmaceuticals Stock?
Vertex Pharmaceuticals is a rare-disease drugmaker with over $10 billion in annual sales. The company's lead drug is the only available treatment for cystic fibrosis, a life-threatening progressive disease.
Vertex Raises Guidance Despite Q2's Bottom-Line Losses
Product revenues increased by 6% to $2.65 billion, in line with market expectations. Management raised full-year product revenue guidance by $100 million.
Vertex Pharmaceuticals Lifts Annual Guidance, Positive Growth For Its Cystic Fibrosis Franchise And Pain Management Pipeline
Thursday, Vertex Pharmaceuticals Incorporated VTRX reported second-quarter revenues of $2.65 billion, almost in line with the consensus of estimate of $2.66 billion.
Vertex Pharma: Driving Growth Through Suzetrigine And Next-Gen Cystic Fibrosis Treatment
Vertex Pharmaceuticals has consistently outperformed the S&P 500 and iShares Biotechnology ETF, reflecting its robust growth and market position. VRTX's diversified pipeline includes cystic fibrosis treatment, Vanzacaftor Triple, and the non-opioid pain management drug Suzetrigine, both with PDUFA dates expected...
Source: https://incomestatements.info
Category: Stock Reports